Cancer Treatment Reviews
Volume 25, Issue 4 , Pages 237-247 , August 1999

Detection of anthracycline-induced cardiotoxicity

  • M.T. Meinardi

      Affiliations

    • Division of Medical Oncology Department of Internal Medicine
    • ,
  • W.T.A.van der Graaf

      Affiliations

    • Division of Medical Oncology Department of Internal Medicine
    • ,
  • D.J.van Veldhuisen

      Affiliations

    • Department of Cardiology, University Hospital Groningen, The Netherlands
    • ,
  • J.A. Gietema

      Affiliations

    • Division of Medical Oncology Department of Internal Medicine
    • ,
  • E.G.E.de Vries

      Affiliations

    • Division of Medical Oncology Department of Internal Medicine
    • ,
  • D.Th. Sleijfer

      Affiliations

    • Division of Medical Oncology Department of Internal Medicine

References 

    REFERENCES
  1. Bristow MR, Thompson PD, Martin RP. Early anthracycline cardiotoxicity. Am J Med. 1978;65:823–832
  2. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6–19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol. 1995;24:352–361
  3. Bleyer WA. The impact of childhood cancer on the United States and the world. CA Cancer J Clin. 1990;40:355–367
  4. Steinberg JS, Cohen AJ, Wasserman AG, Cohen P, Ross AM. Acute arrhythmogenicity of doxorubicin administration. Cancer. 1987;60:1213–1218
  5. Praga C, Beretta G, Vigo PL. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep. 1979;63:827–834
  6. Ferrans VJ. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep. 1978;62:955–961
  7. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672–1677
  8. Von Hoff DD, Layard MW, Basa P. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–717
  9. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302–314
  10. Jain KK, Casper ES, Geller NL. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol. 1985;3:818–826
  11. Nielsen D, Jensen JB, Dombernowsky P. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol. 1990;8:1806–1810
  12. Ryberg M, Nielsen D, Skovsgaard T. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol. 1998;16:3502–3508
  13. Schwartz RG, McKenzie WB, Alexander J. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82:1109–1118
  14. Henderson IC, Allegra JC, Woodcock T. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol. 1989;7:560–571
  15. Torti FM, Bristow MR, Howes AE. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983;99:745–749
  16. Legha SS, Benjamin RS, Mackay B. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133–139
  17. Minow RA, Benjamin RS, Lee ET, Gottlieb JA. Adriamycin cardiomyopathy—risk factors. Cancer. 1977;39:1397–1402
  18. Pratt CB, Ransom JL, Evans WE. Age-related adriamycin cardiotoxicity in children. Cancer Treat Rep. 1978;62:1381–1385
  19. Schaadt B, Kelbaek H. Age and left ventricular ejection fraction identify patients with advanced breast cancer at high risk for development of epirubicin-induced heart failure. J Nucl Cardiol. 1997;4:494–501
  20. Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol. 1993;21:477–479
  21. Lipshultz SE, Lipsitz SR, Mone SM. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738–1743
  22. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141:758–763
  23. Villani F, Comazzi R, Lacaita G. Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C. Med Oncol Tumor Pharmacother. 1985;2:93–97
  24. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 1983;43:460–472
  25. Doroshow JH. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res. 1983;43:4543–4551
  26. Rajagopalan S, Politi PM, Sinha BK, Myers CE. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. 1988;48:4766–4769
  27. Jackson JA, Reeves JP, Muntz KH. Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity. Am J Pathol. 1984;117:140–153
  28. Singal PK, Pierce GN. Adriamycin stimulates low-affinity Ca2+ binding and lipid peroxidation but depresses myocardial function. Am J Physiol. 1986;250:H419–425
  29. Kusuoka H, Futaki S, Koretsune Y. Alterations of intracellular calcium homeostasis and myocardial energetics in acute adriamycin-induced heart failure. J Cardiovasc Pharmacol. 1991;18:437–444
  30. Holmberg SR, Williams AJ. Patterns of interaction between anthraquinone drugs and the calcium- release channel from cardiac sarcoplasmic reticulum. Circ Res. 1990;67:272–283
  31. Wang YX, Korth M. Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium. Circ Res. 1995;76:645–653
  32. Takano H, Ozawa H, Kobayashi I. Myocardial sympathetic dysinnervation in doxorubicin cardiomyopathy. J Cardiol. 1996;27:49–55
  33. Lekakis J, Prassopoulos V, Athanassiadis P, Kostamis P, Moulopoulos S. Doxorubicin-induced cardiac neurotoxicity: study with iodine 123- labeled metaiodobenzylguanidine scintigraphy. J Nucl Cardiol. 1996;3:37–41
  34. Fujita N, Hiroe M, Ohta Y, Horie T, Hosoda S. Chronic effects of metoprolol on myocardial beta-adrenergic receptors in doxorubicin-induced cardiac damage in rats. J Cardiovasc Pharmacol. 1991;17:656–661
  35. Tong J, Ganguly PK, Singal PK. Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol. 1991;260:H909–916
  36. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation. 1996;94:2285–2296
  37. Wilkins MR, Redondo J, Brown LA. The natriuretic-peptide family. Lancet. 1997;349:1307–1310
  38. Schmitt K, Tulzer G, Merl M. Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography: diastolic versus systolic parameters. Eur J Pediatr. 1995;154:201–204
  39. Ganz WI, Sridhar KS, Forness TJ. Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate. Am J Clin Oncol. 1993;16:109–112
  40. Stoddard MF, Seeger J, Liddell NE. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol. 1992;20:62–69
  41. Isner JM, Ferrans VJ, Cohen SR. Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Am J Cardiol. 1983;51:1167–1174
  42. Postma A, Bink-Boelkens MT, Beaufort-Krol GC. Late cardiotoxicity after treatment for a malignant bone tumor. Med Pediatr Oncol. 1996;26:230–237
  43. Lipshultz SE, Colan SD, Gelber RD. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808–815
  44. Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs. 1997;54 Suppl 4:30–35
  45. Sparano JA. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. Semin Oncol. 1998;25:66–71
  46. Lemez P, Maresova J. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone-and daunorubicin-based chemotherapy. Semin Oncol. 1998;25:61–65
  47. Singal PK, Siveski-Iliskovic N, Hill M, Thomas TP, Li T. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J Mol Cell Cardiol. 1995;27:1055–1063
  48. Druck MN, Gulenchyn KY, Evans WK. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer. 1984;53:1667–1674
  49. Lenaz L, Page JA. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev. 1976;3:111–120
  50. Ali MK, Soto A, Maroongroge D. Electrocardiographic changes after adriamycin chemotherapy. Cancer. 1979;43:465–471
  51. Minow RA, Benjamin RS, Lee ET, Gottlieb JA. QRS voltage change with adriamycin administration. Cancer Treat Rep. 1978;62:931–934
  52. Larsen RL, Jakacki RI, Vetter VL. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol. 1992;70:73–77
  53. Schwartz CL, Hobbie WL, Truesdell S, Constine LC, Clark EB. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol. 1993;11:1906–1910
  54. Ferrari S, Figus E, Cagnano R, Iantorno D, Bacci G. The role of corrected QT interval in the cardiologic follow-up of young patients treated with Adriamycin. J Chemother. 1996;8:232–236
  55. Ganz WI, Sridhar KS, Ganz SS. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology. 1996;53:461–470
  56. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900–905
  57. Alexander J, Dainiak N, Berger HJ. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med. 1979;300:278–283
  58. Gottdiener, J. S. Mathisen, D. J. Borer, J. S. et al., Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med, 94
  59. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J. 1983;106:1048–1056
  60. Ritchie JL, Singer JW, Thorning D, Sorensen SG, Hamilton GW. Anthracycline cardiotoxicity: clinical and pathologic outcomes assessed by radionuclide ejection fraction. Cancer. 1980;46:1109–1116
  61. Palmeri ST, Bonow RO, Myers CE. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol. 1986;58:607–613
  62. Hurwitz RA, Siddiqui A, Caldwell RL, Weetman RM, Girod DA. Assessment of ventricular function in infants and children. Response to dobutamine infusion. Clin Nucl Med. 1990;15:556–559
  63. Kuecherer HF, Ruffmann K, Schaefer E, Kuebler W. Doppler echocardiographic assessment of left ventricular filling dynamics in patients with coronary heart disease and normal systolic function. Eur Heart J. 1988;9:649–656
  64. Zarich SW, Arbuckle BE, Cohen LR, Roberts M, Nesto RW. Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol. 1988;12:114–120
  65. Lee BH, Goodenday LS, Muswick GJ. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol. 1987;9:184–188
  66. Marchandise B, Schroeder E, Bosly A. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989;118:92–98
  67. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician’s Rosetta Stone. J Am Coll Cardiol. 1997;30:8–18
  68. Hutter JJ, Sahn DJ, Woolfenden JM, Carnahan Y. Evaluation of the cardiac effects of doxorubicin by serial echocardiography. Am J Dis Child. 1981;135:653–657
  69. Nysom K, Holm K, Lipsitz SR. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998;16:545–550
  70. Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J Clin Oncol. 1997;15:61–68
  71. Jakacki RI, Larsen RL, Barber G. Comparison of cardiac function tests after anthracycline therapy in childhood. Implications for screening. Cancer. 1993;72:2739–2745
  72. Steinherz LJ, Graham T, Hurwitz R. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics. 1992;89:942–949
  73. Giannuzzi P, Temporelli PL, Bosimini E. Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. J Am Coll Cardiol. 1996;28:383–390
  74. Werner GS, Schaefer C, Dirks R, Figulla HR, Kreuzer H. Prognostic value of Doppler echocardiographic assessment of left ventricular filling in idiopathic dilated cardiomyopathy. Am J Cardiol. 1994;73:792–798
  75. Cohen GI, Pietrolungo JF, Thomas JD, Klein AL. A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. J Am Coll Cardiol. 1996;27:1753–1760
  76. Tjeerdsma G, Meinardi MT, van der Graaf WTA. Early detection of anthracycline-induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic parameters. Heart. 1999;81:419–423
  77. Ewer MS, Ali MK, Gibbs HR. Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol. 1994;33:645–649
  78. Sung RY, Huang GY, Shing MK. Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline. Int J Cardiol. 1997;60:239–248
  79. Yeung ST, Yoong C, Spink J, Galbraith A, Smith PJ. Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet. 1991;337:816–818
  80. Weesner KM, Bledsoe M, Chauvenet A, Wofford M. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer. 1991;68:435–438
  81. Klewer SE, Goldberg SJ, Donnerstein RL, Berg RA, Hutter JJ. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol. 1992;19:394–401
  82. Ponikowski P, Anker SD, Chua TP. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1997;79:1645–1650
  83. Yi G, Goldman JH, Keeling PJ. Heart rate variability in idiopathic dilated cardiomyopathy: relation to disease severity and prognosis. Heart. 1997;77:108–114
  84. Fauchier L, Babuty D, Cosnay P, Autret ML, Fauchier JP. Heart rate variability in idiopathic dilated cardiomyopathy: characteristics and prognostic value. J Am Coll Cardiol. 1997;30:1009–1014
  85. Jiang W, Hathaway WR, McNulty S. Ability of heart rate variability to predict prognosis in patients with advanced congestive heart failure. Am J Cardiol. 1997;80:808–811
  86. Brouwer J, van Veldhuisen DJ, Man in ‘t Veld AJ. Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. The Dutch Ibopamine Multicenter Trial Study Group. J Am Coll Cardiol. 1996;28:1183–1189
  87. Benedict CR, Weiner DH, Johnstone DE. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators. J Am Coll Cardiol. 1993;22:146A–153A
  88. Bauch M, Ester A, Kimura B. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer. 1992;69:1492–1497
  89. Yamashita J, Ogawa M, Shirakusa T. Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity. Int J Cancer. 1995;62:542–547
  90. Tikanoja T, Riikonen P, Perkkio M, Helenius T. Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer. Med Pediatr Oncol. 1998;31:73–78
  91. Suzuki T, Hayashi D, Yamazaki T. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J. 1998;136:362–363
  92. O’Brien PJ, Dameron GW, Beck ML. Cardiac troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab Anim Sci. 1997;47:486–495
  93. Lipshultz SE, Rifai N, Sallan SE. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation. 1997;96:2641–2648
  94. Missov E, Calzolari C, Davy JM. Cardiac troponin I in patients with hematologic malignancies. Coron Artery Dis. 1997;8:537–541
  95. Wei CM, Lerman A, Rodeheffer RJ. Endothelin in human congestive heart failure. Circulation. 1994;89:1580–1586
  96. Hiroe M, Ohta Y, Fujita N. Myocardial uptake of 111 In monoclonal antimyosin Fab in detecting doxorubicin cardiotoxicity in rats. Morphological and hemodynamic findings. Circulation. 1992;86:1965–1972
  97. Carrio I, Estorch M, Berna L. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med. 1995;36:2044–2049
  98. Estorch M, Carrio I, Berna L. Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med. 1990;31:1965–1969
  99. Carrio I, Estorch M, Berna L. Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies. Eur J Nucl Med. 1991;18:806–812
  100. Narula J, Strauss HW, Khaw BA. Antimyosin positivity in doxorubicin cardiotoxicity: earlier than the conventional evidence. J Nucl Med. 1993;34:1507–1509
  101. Kremer LCM, Tiel-van Buul MMC, Ubbink MC. Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children. J Clin Oncol. 1999;17:1208–1211
  102. Carrio I, Estorch M, Lopez-Pousa A. Assessing anthracycline cardiotoxicity in the 1990s. Eur J Nucl Med. 1996;23:359–364
  103. Sisson JC, Shapiro B, Meyers L. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med. 1987;28:1625–1636
  104. Imamura Y, Ando H, Mitsuoka W. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol. 1995;26:1594–1599
  105. Henderson EB, Kahn JK, Corbett JR. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation. 1988;78:1192–1199
  106. Wakasugi S, Fischman AJ, Babich JW. Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med. 1993;34:1283–1286
  107. Valdes Olmos RA, ten Bokkel Huinink WW, ten Hoeve RF. Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy. Eur J Cancer. 1995;31A:26–31
  108. Valdes Olmos RA, ten Bokkel Huinink WW, Dewit LG. Iodine-123 metaiodobenzylguanidine in the assessment of late cardiac effects from cancer therapy. Eur J Nucl Med. 1996;23:453–458
  109. Takeishi Y, Sukekawa H, Sakurai T. Noninvasive identification of anthracycline cardiotoxicity: comparison of 123I-MIBG and 123I-BMIPP imaging. Ann Nucl Med. 1994;8:177–182
  110. Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J. 1981;102:709–718
  111. Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978;88:168–175
  112. Friedman MA, Bozdech MJ, Billingham ME, Rider AK. Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA. 1978;240:1603–1606
  113. Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep. 1978;62:857–864
  114. Bristow MR, Lopez MB, Mason JW, Billingham ME, Winchester MA. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer. 1982;50:32–41
  115. Swain SM. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin Oncol. 1998;25:43–47
  116. N Engl J Med. 1992;327:685–691

☆ Correspondence to: M.T. Meinardi, Division of Medical Oncology, Department of Internal Medicine, University Hospital, P.O. Box 30.001, 9700 RB Groningen, The Netherlands. Tel.: +31–50–3616161 Fax: +31–50–3619383 E-mail: m.t.meinardi@thorax.azg.nl

PII: S0305-7372(99)90128-7

doi: 10.1053/ctrv.1999.0128

Cancer Treatment Reviews
Volume 25, Issue 4 , Pages 237-247 , August 1999

Article Tools